TRCT
ACHL

Tower Research Capital (TRC)’s Achilles Therapeutics ACHL Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,772
Closed -$9K – 6390
2022
Q4 		$9K Buy
9,772
+8,966
+1,112% +$15.1K ﹤0.01% 4298
2022
Q3 		$2K Buy
806
+785
+3,738% +$2.22K ﹤0.01% 5640
2022
Q2 		$0 Hold
21
– – ﹤0.01% 6616
2022
Q1 		$0 Buy
+21
New +$75 ﹤0.01% 6650

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Tower Research Capital (TRC)'s ACHL Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of Achilles Therapeutics (ACHL) in Q1 2023, closing a stake of 9,772 shares — an estimated $9K sold.

Tower Research Capital (TRC) first reported a position in ACHL in Q1 2022 and held it in 4 quarters. The position peaked at $9K in Q4 2022. 18 funds tracked by Wall St. Rank hold ACHL as of Q1 2023.

  • Tower Research Capital (TRC) reported no remaining Achilles Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,772 Achilles Therapeutics shares in Q1 2023, an estimated $9K.
  • Tower Research Capital (TRC) first reported a position in Achilles Therapeutics in Q1 2022 and held it in 4 quarters.
  • Tower Research Capital (TRC)'s Achilles Therapeutics position peaked at $9K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.